Analysis of the reentry status of blood donors with reactive bloodborne pathogen screening markers in Hangzhou City.
10.3760/cma.j.cn112150-20221208-01187
- Author:
Ying LU
1
;
Wei DING
2
;
Wen Yan GUO
2
;
Fa Ming ZHU
2
;
Jun ZHANG
3
Author Information
1. Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medical, Hangzhou 310016,China Quality Management Departments, Blood Center of Zhejiang Province, Hangzhou 310052,China.
2. Quality Management Departments, Blood Center of Zhejiang Province, Hangzhou 310052,China.
3. Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medical, Hangzhou 310016,China.
- Publication Type:Journal Article
- MeSH:
Humans;
Blood Donors;
Blood-Borne Pathogens;
Retrospective Studies;
Mass Screening/methods*;
Biomarkers;
HIV Infections;
Nucleic Acids;
Hepatitis B virus
- From:
Chinese Journal of Preventive Medicine
2023;57(10):1565-1570
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the reentry rate of reactive blood donors in the bloodborne pathogen infection screening in Hangzhou City, and analyze the donation behavior of those who successfully returned. Methods: A retrospective analysis of the return data of blood donors with reactive bloodborne pathogen screening markers was conducted at Zhejiang Provincial Blood Center from June 2017 to May 2022. The reentry process for blood donors with reactive bloodborne pathogen screening markers in Hangzhou City is as follows: after the initial screening period of 6 months, donors can voluntarily apply for return to the blood center. Samples are collected and subjected to routine enzyme-linked immunosorbent assay (ELISA) screening for HBsAg, anti-HCV, HIV Ab/Ag, and anti-TP, as well as a single nucleic acid (HIV/HCV/HBV) test. For samples that show non-reactivity in both ELISA and nucleic acid tests, serum biomarker testing for the reasons of exclusion is performed using chemiluminescence immunoassay (CLIA), and those with non-reactivity are allowed to return. Results: A total of 4 583 reactive blood donors who met the criteria for re-entry applied for reentry, out of which 475 applications were received from donors in the Hangzhou area. Among these, 279 donors were successfully readmitted, resulting in a success rate of 58.74% (279/475). By the end of December 2021, out of the 174 donors who successfully returned, 114 donors chose to donate again. They collectively donated 39 530 ml of whole blood and 1 147.2 therapeutic doses of platelets. Among these, 21 donors once again showed reactivity for pathogen infection biomarkers, accounting for 18.42% (21/114). Conclusion: The reentry strategy has somewhat mitigated the attrition of blood donors. Nevertheless, there are instances where donors who were successfully readmitted show reactivity once more in the screening for pathogen infection biomarkers.
